Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?

References

• Fabiani S, Fallahi P, Ferrari SM, et al. Hepatitis C virus infection and development of type 2 diabetes mellitus: systematic review and meta-analysis of the literature. Rev Endocr Metab Disord. 2018;19(4):405–420. doi:10.1007/s11154017-9440-1
   Web of Science ®Google Scholar
• Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality? Dig Liver Dis. 2016;48(2):105–111. doi:10.1016/j.dld.2015.10.016
   PubMedGoogle Scholar
• Kwon S, Kim S, Kwon O, et al. Prognostic significance of glycaemic control in patients with HBV and HCV related cirrhosis and diabetes mellitus. Diabetic Med. 2005;22(11):1530–1535. doi:10.1111/j.14645491.2005.01687.x
   Web of Science ®Google Scholar
• Drazilova S, Gazda J, Janicko M, et al. Chronic hepatitis C association with diabetes mellitus and cardiovascular risk in the era of DAA therapy. Can J Gastroenterol Hepatol. 2018;(2018:11. doi:10.1155/2018/6150861
   Web of Science ®Google Scholar
• Schinazi R, Halfon P, Marcellin P, et al. HCV direct acting antiviral agents: the best interferon free combinations. Liver Int. 2014;34:69–78. doi:10.1111/liv.12423
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146(5):1176–1192. doi:10.1053/j.gastro.2014.03.003
   PubMed Web of Science ®Google Scholar
• Gastaldi G, Gomes D, Schneiter P, et al. Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients. PLoS One. 2019;14(6):e0217751. doi:10.1371/journal.pone.0217751
   Web of Science ®Google Scholar
• Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–149. doi:10.1016/j.diabres.2013.11.002
   PubMed Web of Science ®Google Scholar
• El-Zanaty F, Way A. Egypt demographic and health survey (2008). Ministry of Health, El-Zanaty and Associates, and Macro International; 2009: 431.
   Google Scholar
• Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436. doi:10.3748/wjg.v13.i17.2436
   PubMed Web of Science ®Google Scholar
• Sicras Mainar A, Navarro Artieda R, Hernández I, et al. Prevalence of the potential drug–drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain. Gastroenterol Hepatol. 2019;42(8):465–475. doi:10.1016/j.gastre.2019.09.001
   Web of Science ®Google Scholar
• Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis. 2008;28(1):110–122. doi:10.1055/s-2008-1040325
   PubMed Web of Science ®Google Scholar
• Pace CA, Uebelacker LA. Addressing unhealthy substance use in primary care. Med Clin. 2018;102(4):567–586. doi:10.1016/j.mcna.2018.02.004
   Web of Science ®Google Scholar
• Jonas DE, Garbutt JC. Screening and counseling for unhealthy alcohol use in primary care settings. Med Clin. 2017;101(4):823–837. doi:10.1016/j.mcna.2017.03.011
   Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi:10.1002/hep.21178
   PubMed Web of Science ®Google Scholar
• Unnikrishnan R, Anjana RM, Mohan V. Drugs affecting HbA1c levels. Indian J Endocrinol Metab. 2012;16(4):528–531. doi:10.4103/22308210.98004
   PubMedGoogle Scholar
• Dawson B, Trapp R. Basic and clinical biostatistics. In: Lange Medical Books. 3rd ed. Oxford: London and Boston; 2001.
   Google Scholar
• White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831–844. doi:10.1016/j.jhep.2008.08.006
   PubMed Web of Science ®Google Scholar
• Burman BE, Bacchetti P, Ayala CE, et al. Liver inflammation is a risk factor for prediabetes in at risk latinos with and without hepatitis C infection. Liver Int. 2015;35(1):101–107. doi:10.1111/liv.12676
   Web of Science ®Google Scholar
• Drazilova S, Janicko M, Skladany L, et al. Glucose metabolism changes in patients with chronic hepatitis C treated with direct acting antivirals. Can J Gastroenterol Hepatol. 2018;(2018:6095097. doi:10.1155/2018/6095097
   Web of Science ®Google Scholar
• Deltenre P, Louvet A, Lemoine M, et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol. 2011;55(6):1187–1194. doi:10.1016/j.jhep.2011.03.010
   Web of Science ®Google Scholar
• Qing S, Ji D, Li B, et al. Improvement of glucose and lipid metabolism with pegylated interferon-α plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus. Ann Saudi Med. 2015;35(4):293–297. doi:10.5144/0256-4947.2015.293
   Web of Science ®Google Scholar
• Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008;48(5):721–727. doi:10.1016/j.jhep.2007.11.022
   PubMed Web of Science ®Google Scholar
• Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49(3):739–744. doi:10.1002/hep.22703
   PubMed Web of Science ®Google Scholar
• Marshall AD, Cunningham EB, Nielsen S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3(2):125–133. doi:10.1016/S24681253(17)30284-4
   PubMed Web of Science ®Google Scholar
• Butt AA, Yan P, Aslam S, et al. Hepatitis C Virus (HCV) treatment with directly acting agents reduces the risk of incident diabetes: results from electronically retrieved cohort of HCV infected veterans (ERCHIVES). Clin Infect Dis. 2019;70(6):1153–1160.
   Web of Science ®Google Scholar
• Ikeda A, Ikeda K, Takai A, et al. Hepatitis C treatment with sofosbuvir and ledipasvir accompanied by immediate improvement in hemoglobin A1c. Digestion. 2017;96(4):228–230. doi:10.1159/000484237
   PubMed Web of Science ®Google Scholar
• Meissner EG, Lee YJ, Osinusi A, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1–infected patients. Hepatology. 2015;61(3):790–801. doi:10.1002/hep.27424
   Web of Science ®Google Scholar
• Pavone P, Tieghi T, d’Ettorre G, et al. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect. 2016;22(5):462.e1-.e3. doi:10.1016/j.cmi.2015.12.030
   Web of Science ®Google Scholar
• Abdel Alem S, Elsharkawy A, Fouad R, et al. Improvement of glycemic state among responders to Sofosbuvir based treatment regimens: single center experience. J Med Virol. 2017;89(12):2181–2187. doi:10.1002/jmv.24897
   Web of Science ®Google Scholar
• Dawood AA, Nooh MZ, Elgamal AA. Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4. Diabetes Metab J. 2017;41(4):316–321. doi:10.4093/dmj.2017.41.4.316
   Web of Science ®Google Scholar
• El Sagheer G, Soliman E, Ahmad A, et al. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs. Libyan J Med. 2018;13(1):1435124. doi:10.1080/19932820.2018.1435124
   PubMed Web of Science ®Google Scholar
• Soriano V, Barreiro P, de Mendoza C. Hypoglycemia in a diabetic patient during hepatitis C therapy. Hepatology. 2016;63(6):2065–2066. doi:10.1002/hep.28137
   Web of Science ®Google Scholar
• Hum J, Jou JH, Green PK, et al. Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus. Diabetes Care. 2017;40(9):1173–1180. doi:10.2337/dc17-0485
   Web of Science ®Google Scholar
• Ciancio A, Bosio R, Bo S, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct acting antiviral agents. J Med Virol. 2018;90(2):320–327. doi:10.1002/jmv.24954
   PubMed Web of Science ®Google Scholar
• Tran T, Mehta D, Goldstein A, et al. Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: results from clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin. J Hepatol. 2017;66(1):S302. doi:10.1016/S01688278(17)
   Web of Science ®Google Scholar
• Morales AL, Junga Z, Singla MB, et al. Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. World J Hepatol. 2016;8(35):1557–1563. doi:10.4254/wjh.v8.i35.1557
   Google Scholar
• Beig J, Orr D, Harrison B, et al. Hepatitis C virus eradication with new interferon free treatment improves metabolic profile in hepatitis C virus related liver transplant recipients. Liver Transpl. 2018;24(8):1031–1039. doi:10.1002/lt.25060
   Web of Science ®Google Scholar
• Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–176. doi:10.1016/S24681253(16)
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G, Bugianesi E, Bouserhal T, et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut. 2007;56(9):1296–1301. doi:10.1136/gut.2006.107946
   Web of Science ®Google Scholar
• Elgouhari HM, Zein CO, Hanouneh I, et al. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci. 2009;54(12):2699–2705. doi:10.1007/s10620-0080683-2
   PubMed Web of Science ®Google Scholar
• Montenegro L, De Michina A, Misciagna G, et al. Virus C hepatitis and type 2 diabetes: a cohort study in southern Italy. Am J Gastroenterol. 2013;108(7):1108. doi:10.1038/ajg.2013.90
   PubMed Web of Science ®Google Scholar
• Giordanino C, Bugianesi E, Smedile A, et al. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis c infection by response to treatment: results of a cohort study. Am J Gastroenterol. 2008;103(10):2481–2487. doi:10.1111/j.15720241.2008.02002.x
   PubMed Web of Science ®Google Scholar
• Chaudhury CS, Sheehan J, Chairez C, et al. No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV. J Infect Dis. 2017;217(1):47–50. doi:10.1093/infdis/jix517
   Web of Science ®Google Scholar
• Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Ther Adv Gastrointest Endosc. 2011;4(4):249–263. doi:10.1177/1756283X11403809
   Google Scholar
• Sumie S, Kawaguchi T, Kawaguchi A, et al. Effect of pioglitazone on outcome following curative treatment for hepatocellular carcinoma in patients with hepatitis C virus infection: a prospective study. Mol Clin Oncol. 2015;3(1):115–120. doi:10.3892/mco.2014.435
   Google Scholar
• Bonkovsky HL, Azar R, Bird S, et al. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci. 2002;47(7):1632–1637. doi:10.1023/A:1015895925374
   PubMed Web of Science ®Google Scholar